β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation
Diabetes · 2024
DOI: 10.2337/db24-0729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Anneliese J Flatt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Insulin-Secreting Cells, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK NIH HHS.
Abstract (Originalsprache)
Transplanted islet functional β-cell mass is measured by the β-cell secretory capacity derived from the acute insulin response to glucose-potentiated arginine (AIRpot), however, data are limited beyond one-year post-transplant for individuals with type 1 diabetes. We evaluated changes in β-cell secretory capacity in a single-center longitudinal analysis and examined relationships with measures of islet cell hormone metabolism and clinical measures of graft function (mixed-meal tolerance test [MMTT] C-peptide, BETA-2 score, and continuous glucose monitoring [CGM]). Eleven individuals received purified human pancreatic islets over one or two intra-portal infusions to achieve insulin-independence and were followed over a median (IQR) 6 (5-7) years. β-cell secretory capacity remained stable over 3-years before declining. Fasting glucagon and proinsulin secretory ratios under glucose-potentiation were inversely correlated with AIRpot. A functional β-cell mass of 40% normal predicted insulin-independence and was strongly predicted by MMTT C-peptide-to-glucose and BETA-2 score. A functional β-cell mass of >20% predicted excellent glycemic outcomes including ≤1% time <60 mg/dL, ≤2% time >180 mg/dL and ≥90% time-inrange 70-180 mg/dL. β-cell replacement approaches should target a functional β-cell mass >40% to provide sufficient islet reserve for sustained insulin-independence. MMTT C-peptide-to-glucose and BETA-2 score can inform changes in functional β-cell mass in the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
- Department of Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
- Department of Mathematics, West Chester University of Pennsylvania, West Chester, PA.
- Division of Transplantation, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
ORCID-Profile: Michael R Rickels
Förderung
- NCATS NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- NIDDK NIH HHS
Zitieren
APA
Flatt, A. J., Matus, A. M., Gallop, R. J., Markmann, E., Dalton-Bakes, C., Peleckis, A. J., Liu, C., Naji, A., & Rickels, M. R. (2024). β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation. Diabetes. https://doi.org/10.2337/db24-0729
Vancouver
Flatt AJ, Matus AM, Gallop RJ, Markmann E, Dalton-Bakes C, Peleckis AJ, et al. β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation. Diabetes. 2024. doi:10.2337/db24-0729
BibTeX
@article{Flatt2024,
author = {Flatt, Anneliese J and Matus, Austin M and Gallop, Robert J and Markmann, Eileen and Dalton-Bakes, Cornelia and Peleckis, Amy J and Liu, Chengyang and Naji, Ali and Rickels, Michael R},
title = {β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db24-0729}
}
EUVIMED